April 13, 2018 07:02 AM EDT

Retire? Bill Chin’s tried it three times, and he’d rather be working at Frequency Therapeutics

John Carroll

Editor & Founder

William Chin’s resume sprints through 25 years of prestigious posts: Harvard professor, a senior VP of global research at Eli Lilly, back to Harvard as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Retire? Bill Chin’s tried it three times, and he’d rather be working at Frequency Therapeutics

John Carroll

Editor & Founder

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Applied Therapeutics' rare disease drug gets a CRL

Re­tire? Bill Chin’s tried it three times, and he’d rather be work­ing at Fre­quen­cy Ther­a­peu­tics

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Retire? Bill Chin’s tried it three times, and he’d rather be working at Frequency Therapeutics

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Applied Therapeutics' rare disease drug gets a CRL